
-
Eloxx Pharmaceuticals OTC Markets OTCPK:ELOX Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Location: 480 Arsenal Way, Watertown, MA, 02472, United States | Website: https://www.eloxxpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
13.95M
Cash
4.775M
Avg Qtr Burn
-4.498M
Short % of Float
0.74%
Insider Ownership
5.82%
Institutional Own.
3.98%
Qtr Updated
09/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELX-02 Details Lung disease, Cystic fibrosis, Glabellar lines | Phase 2 Update | |
ELX-02 Details Rare genetic disease, Alport Syndrome | Phase 2 Update | |
ZKN-013 Details Rare genetic disease, Junctional epidermolysis bullosa, Recessive dystrophic epidermolysis bullosa | Phase 1 Data readout | |
ELX-02 Details Rare genetic disease | Failed Discontinued |